Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX) Head to Head Analysis

Biosig Technologies (NASDAQ:STEX) and Perspective Therapeutics (NASDAQ:CATX) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Risk and Volatility

Biosig Technologies has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Biosig Technologies and Perspective Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1	0	0	0	1.00
Perspective Therapeutics	0	0	6	0	3.00

Perspective Therapeutics has a consensus target price of $11.17, indicating a potential upside of 141.18%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Perspective Therapeutics is more favorable than Biosig Technologies.

Earnings & Valuation

This table compares Biosig Technologies and Perspective Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40,000.00	11,930.10	-$10.33 million	($1.35)	-2.21
Perspective Therapeutics	N/A	N/A	N/A	($0.90)	-5.14

Perspective Therapeutics has lower revenue, but higher earnings than Biosig Technologies. Perspective Therapeutics is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biosig Technologies and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	N/A	-64.96%
Perspective Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 3.7% of Perspective Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Perspective Therapeutics beats Biosig Technologies on 7 of the 9 factors compared between the two stocks.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

About Perspective Therapeutics

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.